Adverum Biotechnologies and Editas Medicine have extended their collaboration agreement to explore the delivery of genome editing medicines to treat inherited retinal diseases, Adverum announced in a press release.
The companies are extending the research period through the third quarter of 2018, and Editas has a series of options exercisable between now and August 2020, the release said.
The collaboration focuses on utilizing Adverum’s adeno-associated viral vectors to deliver Editas’ CRISPR-based genome editing technologies in order to develop therapies for eye diseases, according
Uncategorized